These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

164 related articles for article (PubMed ID: 20807504)

  • 21. High affinity interaction of integrin alpha4beta1 (VLA-4) and vascular cell adhesion molecule 1 (VCAM-1) enhances migration of human melanoma cells across activated endothelial cell layers.
    Klemke M; Weschenfelder T; Konstandin MH; Samstag Y
    J Cell Physiol; 2007 Aug; 212(2):368-74. PubMed ID: 17352405
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Synthesis and biological evaluation of novel pyridazinone-based alpha4 integrin receptor antagonists.
    Gong Y; Barbay JK; Dyatkin AB; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Ballentine SA; Hageman WE; Masucci JA; Maryanoff BE; Damiano BP; Andrade-Gordon P; Hlasta DJ; Hornby PJ; He W
    J Med Chem; 2006 Jun; 49(11):3402-11. PubMed ID: 16722660
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Contribution of alpha4beta1 integrin to the antiallergic effect of levocabastine.
    Qasem AR; Bucolo C; Baiula M; Spartà A; Govoni P; Bedini A; Fascì D; Spampinato S
    Biochem Pharmacol; 2008 Sep; 76(6):751-62. PubMed ID: 18680729
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Potent cyclic monomeric and dimeric peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion based on the Ile-Leu-Asp-Val tetrapeptide.
    Dutta AS; Crowther M; Gormley JJ; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Jamieson A; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
    J Pept Sci; 2000 Jul; 6(7):321-41. PubMed ID: 10946997
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Potent alpha 4 beta 1 peptide antagonists as potential anti-inflammatory agents.
    Jackson DY; Quan C; Artis DR; Rawson T; Blackburn B; Struble M; Fitzgerald G; Chan K; Mullins S; Burnier JP; Fairbrother WJ; Clark K; Berisini M; Chui H; Renz M; Jones S; Fong S
    J Med Chem; 1997 Oct; 40(21):3359-68. PubMed ID: 9341911
    [TBL] [Abstract][Full Text] [Related]  

  • 26. In vitro exposure to paclitaxel modulates integrin expression by human T lymphocytes and inhibits T cell adhesion to breast carcinoma cells.
    Bhan V; Mader JS; Hoskin DW
    Oncol Rep; 2004 Apr; 11(4):893-7. PubMed ID: 15010891
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Aza-bicyclic amino acid carboxamides as alpha4beta1/alpha4beta7 integrin receptor antagonists.
    Dyatkin AB; Gong Y; Miskowski TA; Kimball ES; Prouty SM; Fisher MC; Santulli RJ; Schneider CR; Wallace NH; Hornby PJ; Diamond C; Kinney WA; Maryanoff BE; Damiano BP; He W
    Bioorg Med Chem; 2005 Dec; 13(24):6693-702. PubMed ID: 16112583
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Potent cyclic peptide inhibitors of VLA-4 (alpha4beta1 integrin)-mediated cell adhesion. Discovery of compounds like cyclo(MePhe-Leu-Asp-Val-D-Arg-D-Arg) (ZD7349) compatible with depot formulation.
    Dutta AS; Gormley JJ; Coath M; Hassall L; Hayward CF; Gellert PR; Kittlety RS; Alcock PJ; Ferguson R; Halterman T; Jamieson A; Moors JA; Moores JM; Rees A; Wood LJ; Reilly CF; Haworth D
    J Pept Sci; 2000 Aug; 6(8):398-412. PubMed ID: 10969869
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Intracellular signaling required for CCL25-stimulated T cell adhesion mediated by the integrin alpha4beta1.
    Parmo-Cabañas M; García-Bernal D; García-Verdugo R; Kremer L; Márquez G; Teixidó J
    J Leukoc Biol; 2007 Aug; 82(2):380-91. PubMed ID: 17510295
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Ligand binding of leukocyte integrin very late antigen-4 involves exposure of sulfhydryl groups and is subject to redox modulation.
    Liu SY; Tsai MY; Chuang KP; Huang YF; Shieh CC
    Eur J Immunol; 2008 Feb; 38(2):410-23. PubMed ID: 18196516
    [TBL] [Abstract][Full Text] [Related]  

  • 31. The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma.
    Ravensberg AJ; Luijk B; Westers P; Hiemstra PS; Sterk PJ; Lammers JW; Rabe KF
    Allergy; 2006 Sep; 61(9):1097-103. PubMed ID: 16918513
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Integrin alpha4beta1 function is required for cell survival in developing retina.
    Leu ST; Jacques SA; Wingerd KL; Hikita ST; Tolhurst EC; Pring JL; Wiswell D; Kinney L; Goodman NL; Jackson DY; Clegg DO
    Dev Biol; 2004 Dec; 276(2):416-30. PubMed ID: 15581875
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Modulation of integrin-mediated intercellular adhesion during the interaction of thymocytes with stromal cells expressing VLA-4 and LFA-1 ligands.
    St-Pierre Y; Hugo P; Legault D; Tremblay P; Potworowski EF
    Eur J Immunol; 1996 Sep; 26(9):2050-5. PubMed ID: 8814245
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Paxillin selectively associates with constitutive and chemoattractant-induced high-affinity alpha4beta1 integrins: implications for integrin signaling.
    Hyduk SJ; Oh J; Xiao H; Chen M; Cybulsky MI
    Blood; 2004 Nov; 104(9):2818-24. PubMed ID: 15242880
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Design, synthesis and binding properties of a fluorescent α₉β₁/α₄β₁ integrin antagonist and its application as an in vivo probe for bone marrow haemopoietic stem cells.
    Cao B; Hutt OE; Zhang Z; Li S; Heazlewood SY; Williams B; Smith JA; Haylock DN; Savage GP; Nilsson SK
    Org Biomol Chem; 2014 Feb; 12(6):965-78. PubMed ID: 24363056
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Modeling the molecular basis for α4β1 integrin antagonism.
    Hutt OE; Saubern S; Winkler DA
    Bioorg Med Chem; 2011 Oct; 19(19):5903-11. PubMed ID: 21889349
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Orally available and efficacious α4β1/α4β7 integrin inhibitors.
    Xu YZ; Smith JL; Semko CM; Rossiter KI; Fukuda JY; Dappen MS; Quincy DA; Konradi AW; Mao W; Welch B; Dreyer ML; Samant B; Zhang H; Lugar J; Liao Z; Henschel C; Petersen E; Vandevert C; Shoemaker M; Wehner N; Mutter L; Shopp G; Krimm M; Chen L; Wipke B; Dofiles L; Gallager I; Sauer JM; Messersmith EK; Pleiss MA; Bard F; Yednock TA
    Bioorg Med Chem Lett; 2013 Aug; 23(15):4370-3. PubMed ID: 23777782
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Identification of N-acyl 4-(3-pyridonyl)phenylalanine derivatives and their orally active prodrug esters as dual acting α4β1 and α4β7 receptor antagonists.
    Tilley JW; Sidduri A; Lou J; Kaplan G; Tare N; Cavallo G; Frank K; Pamidimukkala A; Choi DS; Gerber L; Railkar A; Renzetti L
    Bioorg Med Chem Lett; 2013 Feb; 23(4):1036-40. PubMed ID: 23312471
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Highly constrained bicyclic VLA-4 antagonists.
    Chang LL; Truong Q; Doss GA; MacCoss M; Lyons K; McCauley E; Mumford R; Forrest G; Vincent S; Schmidt JA; Hagmann WK
    Bioorg Med Chem Lett; 2007 Feb; 17(3):597-601. PubMed ID: 17118652
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Solid-phase synthesis of dual alpha4beta1/alpha4beta7 integrin antagonists: two scaffolds with overlapping pharmacophores.
    Castanedo GM; Sailes FC; Dubree NJ; Nicholas JB; Caris L; Clark K; Keating SM; Beresini MH; Chiu H; Fong S; Marsters JC; Jackson DY; Sutherlin DP
    Bioorg Med Chem Lett; 2002 Oct; 12(20):2913-7. PubMed ID: 12270174
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 9.